Currently, there are 4.71M common shares owned by the public and among those 3.31M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -7.38% and -88.60% over the past three months. CDT shares are trading -83.53% year to date (YTD), with the 12-month market performance down to -99.56% lower. It has a 12-month low price of $1.09 and touched a high of $392.00 over the same period. CDT has an average intraday trading volume of 3.50 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -24.08%, -74.42%, and -97.63% respectively.
Institutional ownership of Conduit Pharmaceuticals Inc (NASDAQ: CDT) shares accounts for 1.86% of the company’s 4.71M shares outstanding.
It has a market capitalization of $5.32M and a beta (3y monthly) value of 2.23. The earnings-per-share (ttm) stands at -$21.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.55% over the week and 20.88% over the month.
Analysts forecast that Conduit Pharmaceuticals Inc (CDT) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and 0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0.
